Skip to content

Impact of Muscle Temperature on Muscle Growth and Breakdown: Cooling During Resistance Training

Impact of Muscle Temperature on Muscle Growth and Breakdown: Cooling During Resistance Training

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05302791
Enrollment
12
Registered
2022-03-31
Start date
2022-04-19
Completion date
2022-10-01
Last updated
2024-10-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Exercise Training

Keywords

Resistance Exercise, Muscle Cooling

Brief summary

The purpose of this study is to examine the effect of human skeletal muscle temperature during resistance exercise on myogenic and proteolytic signaling. Subjects will perform bilateral resistance exercise bouts at an intensity that should stimulate a muscle growth response in the Vastus Lateralis. During the resistance exercise, the subjects will receive a cold (10°C) intervention on the experimental limb, while receiving a neutral temperature intervention (22°C) on the control limb.

Detailed description

A total of 2 visits to the laboratory will be required following the signing of informed consent. All visits will take place at the University of Nebraska Exercise Physiology Laboratory. Initial Visit (\ 1.5-2 hours): Height and weight will be measured using a medical scale. Body fat will be assessed with hydrostatic weighing using an electronic load cell based system (Exertech, Dresbach, MN) correcting for residual lung volume, or Bioelectrical Impedance Analysis body composition analyzer (InBodyUSA, Cerritos, CA) if needed. Subjects will then perform a 12 Repetition (12RM) Max Test for bilateral seated leg press and seated leg extension using the following protocol on isotonic exercise machines at a weight designed to create failure between 8 and 12 repetitions. Following a short warm-up on a cycle ergometer, the subjects proceed with a bilateral leg press warm-up consisting of one set of ten repetitions at a self-determined light load, then one set of 5 repetition at a self-determined moderate load, and one set of 1 repetition at a predicted 12 rep maximum as predicted in relation to their Fat Free Mass. During the warm-up subjects will be coached on form, and observed for their ability to complete the repetition max test. Weight for the test will be altered to suit the subject's ability to complete approximately 12 repetitions. Once the desired weight is determined, subjects will be asked to complete as many repetitions as possible until the subject can no longer complete a repetition using a full range of motion. An identical testing protocol is then performed for the leg extension. This data will be used to estimate a 12RM workload, that would be appropriate for hypertrophic growth using the Watham equation . Experimental Visit (\ 6.5-8 hours): Participants will be instructed to arrive to the lab having fasted overnight, and they will be asked to avoid strenuous activity, alcohol consumption, tobacco use, and drug use for the 24 hour period leading up to experimental trial. Subjects will complete the following experimental protocol briefly described: consume a small meal, a pre-exercise muscle biopsy, precool for 30 minutes, complete the exercise intervention, immediately post-exercise biopsy, 4 hour recovery with cooling, and post-recovery biopsy. At three time points (pre-exercise, immediately post-exercise, and post-4-hour recovery), skin temperature, muscle temperature, blood flow, and muscle tissue biopsies will be taken. Details are as followed: Meal When subjects arrive a consistent meal will be provided to standardize dietary intake. Food choices will be given to participants to create a meal between 700-800 calories, containing approximately 25-35 g of protein, 75-85 g of carbohydrates, and 35-45 g of fat. These foods will be made-up of commercially available pre-packaged foods. They will have approximately 30 minutes to consume their meal. Cooling protocol Subjects will have Game Ready Med 4 elite thigh wraps around each thigh. This system circulates cooled liquid through a wrap specifically fitted for different body segments. One thigh will be cooled while the other thigh will be wrapped with the cuff, but not have any liquid circulating through it. These wraps do provide slight compression and thus it is important to apply the wraps to both legs. Each leg is assigned to either cold experimental group or control, will be randomized and counter-balanced between subjects. The liquid temperature circulating through the thermal wraps will be set to 10°C. The thermal wraps will be worn during a 30 minute cool down period prior to the exercise bout, during the exercise intervention, and during a 4 hour recovery period. Exercise Intervention The subjects will complete an intervention designed to stimulate the muscle growth signaling pathway (hypertrophy) in the Vastus Lateralis (outer thigh), via bilateral seated leg press and bilateral seated leg extension on isotonic exercise machines. Subjects will perform four sets of bilateral leg press exercises at the weight determined to be their 12 RM from the repetition max test. This should allow completion to failure of 8-12 repetitions. So, if more than 12 reps are able to be completed, weight will be added to the resistance for the subsequent sets. Conversely, if less than 8 reps lead to failure, the weight should be reduced for the subsequent sets. Constant dialogue with subjects will give investigators the ability to monitor set weights to maximize a hypertrophic response. Subjects will be allowed 2 minute of rest between each set. Upon completion of 4 sets, the subjects will be given 5 minutes of rest prior to repeating this protocol for bilateral leg extensions. Biopsies A total of 6 muscle biopsies (1 per leg) will be obtained from the vastus lateralis (outer thigh) muscle. One from each leg for each of the 3 collection time-points, pre-exercise, immediately post-exercise, and post-4-hour recovery. Briefly, the area above the vastus lateralis muscle belly will be shaved and cleaned with alcohol. 1% xylocaine is then injected under the skin with a 25 ga hypodermic needle. The area is then further disinfected with betadine, and a sterile fenestrated drape is placed over the biopsy site. Using sterile techniques, a small incision is made through the skin (\ 5mm) and the Bergstrom biopsy needle is inserted through the incision into the belly of the muscle. The Bergstrom needle then takes a small clip of muscle (\ 50mg) and is removed from the muscle and stored in a chemical stabilizer. Slight pressure is held over the incision for approximately 2 minutes and is then closed using steri-strips and a band-aid with antibiotic ointment. Intramuscular Temperature Using the incision from the muscle biopsy, a hypodermic (\ 26ga) thermocouple (Physitemp Instruments LLC, Clifton, NJ) that is smaller than the needle used to inject the xylocaine will be inserted into the belly of the muscle to measure intramuscular temperature. The thermocouple readings stabilize in approximately 3 seconds and the thermocouple is then removed. Recordings for intramuscular temperature will be collected during the biopsy process following the intervention. Skin Temperature Skin Temperature will be measured on the surface of each thigh using a skin thermistor (Physitemp Instruments LLC, Clifton, NJ), infrared digital thermometer, and/or using an infrared thermal camera. Measurements will be taken at the same time as the intramuscular. The thermistor is simply placed on the skin for approximately 3 seconds and is then recorded. The infrared thermal camera can measure and record surface temperatures for a field of multiple surfaces.

Interventions

DEVICEMuscle Cooling

Cooling wrap will be set to 10°C

OTHERResistance Exercise

Resistance Machines (Leg Press and Knee extension). 12 rep Max

Sponsors

University of Nebraska
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE

Intervention model description

Each Subject acts as their own control in a de facto repeated measures design, where there is a Single bilateral exercise bout, with experimental and control assignment to individual limbs.

Eligibility

Sex/Gender
ALL
Age
19 Years to 45 Years
Healthy volunteers
Yes

Inclusion criteria

* Any male or female who is 19-45 of age and is considered * low risk for physical activity based on the American College of Sports Medicine (ACSM) guidelines * recreationally active during the 6 weeks prior to participation by meeting the ACSM minimum activity guidelines

Exclusion criteria

* Any person outside of the age range of 19-45 * not considered 'low risk' on the ACSM Risk Stratification Form * not meeting the exercise requirements for the preceding 6 weeks will be excluded. * self-report of a history of joint or muscular injury that would prevent them from safely completing the required activities * self-report of taking prescription drugs or supplements that may interfere with this research * self-report allergy to Xylocaine * pregnant * breast feeding * self-report sensitivity to heat or cold

Design outcomes

Primary

MeasureTime frameDescription
RT-qPCR for Ribosomal Protein L3 Like (RPL3L)4-hours post ExerciseRT-qPCR for Ribosomal Protein L3 Like (RPL3L) \[mRNA response of RPL3L\] Fold change calculated using the delta, delta CT method relative to stable reference genes and pre-exercise measures.
RT-qPCR for Myogenin (MYOG)4-hours post ExerciseRT-qPCR for Myogenin (MYOG) \[mRNA response of MYOG\] Fold change calculated using the delta, delta CT method relative to stable reference genes and pre-exercise measures.
RT-qPCR for Ribosomal Protein S3 (RPS3)4-hours post ExerciseRT-qPCR for Ribosomal Protein S3 (RPS3) \[mRNA response of RPS3\] Fold change calculated using the delta, delta CT method relative to stable reference genes and pre-exercise measures.
RT-qPCR for Forkhead Box O3 (FOXO3a)4-hours post ExerciseRT-qPCR for Forkhead Box O3 (FOXO3a) \[mRNA response FOXO3a\] Fold change calculated using the delta, delta CT method relative to stable reference genes and pre-exercise measures.
RT-qPCR for Tripartite Motif Containing 63 (TRIM63)4-hours post ExerciseRT-qPCR for Tripartite Motif Containing 63 (TRIM63) \[mRNA response of TRIM63\] Fold change calculated using the delta, delta CT method relative to stable reference genes and pre-exercise measures.
RT-qPCR for Growth/Differentiation Factor 8 (MSTN)4-hours post ExerciseRT-qPCR for Growth/Differentiation Factor 8 (MSTN) \[mRNA response of MSTN\] Fold change calculated using the delta, delta CT method relative to stable reference genes and pre-exercise measures.
RT-qPCR for Myogenic Factor 5 (MYF5)4-hours post ExerciseRT-qPCR for Myogenic Factor 5 (MYF5) \[mRNA response of MYF5\] Fold change calculated using the delta, delta CT method relative to stable reference genes and pre-exercise measures.
RT-qPCR for Myogenic Factor 6 (MYF6)4-hours post ExerciseRT-qPCR for Myogenic Factor 6 (MYF6) \[mRNA response of MYF6\] Fold change calculated using the delta, delta CT method relative to stable reference genes and pre-exercise measures.
RT-qPCR for Myocyte Enhancer Factor 2A (MEF2a)4-hours post ExerciseRT-qPCR for Myocyte Enhancer Factor 2A (MEF2a) \[mRNA response of MEF2a\] Fold change calculated using the delta, delta CT method relative to stable reference genes and pre-exercise measures.
RT-qPCR for Myogenic Differentiation 1 (MYOD1)4-hours post ExerciseRT-qPCR for Myogenic Differentiation 1 (MYOD1) \[mRNA response of MYOD1\] Fold change calculated using the delta, delta CT method relative to stable reference genes and pre-exercise measures.

Secondary

MeasureTime frameDescription
Skin Temperature4-hours post ExerciseSurface Temperature of the skin
Muscle Temperature4-hours post ExerciseIntramuscular Temperature

Countries

United States

Participant flow

Participants by arm

ArmCount
All Participants
all participants have one leg serving as the experimental (10 degrees C cooling wrap) and the other as the control (no cooling) before, during, and after resistance exercise.
12
Total12

Baseline characteristics

CharacteristicAll Participants
Age, Continuous26.5 years
STANDARD_DEVIATION 2.9
body composition20.8 % fat
STANDARD_DEVIATION 13.5
height1.71 meters
STANDARD_DEVIATION 0.08
Race and Ethnicity Not Collected— Participants
Region of Enrollment
United States
12 participants
Sex: Female, Male
Female
4 Participants
Sex: Female, Male
Male
8 Participants
weight77.3 kg
STANDARD_DEVIATION 15.9

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 12
other
Total, other adverse events
0 / 12
serious
Total, serious adverse events
0 / 12

Outcome results

Primary

RT-qPCR for Forkhead Box O3 (FOXO3a)

RT-qPCR for Forkhead Box O3 (FOXO3a) \[mRNA response FOXO3a\] Fold change calculated using the delta, delta CT method relative to stable reference genes and pre-exercise measures.

Time frame: 4-hours post Exercise

ArmMeasureValue (MEAN)Dispersion
Muscle CoolingRT-qPCR for Forkhead Box O3 (FOXO3a)1.24 fold changeStandard Deviation 0.69
ControlRT-qPCR for Forkhead Box O3 (FOXO3a)1.30 fold changeStandard Deviation 0.98
p-value: 0.609ANOVA
Primary

RT-qPCR for Growth/Differentiation Factor 8 (MSTN)

RT-qPCR for Growth/Differentiation Factor 8 (MSTN) \[mRNA response of MSTN\] Fold change calculated using the delta, delta CT method relative to stable reference genes and pre-exercise measures.

Time frame: 4-hours post Exercise

ArmMeasureValue (MEAN)Dispersion
Muscle CoolingRT-qPCR for Growth/Differentiation Factor 8 (MSTN).44 fold changeStandard Deviation 0.3
ControlRT-qPCR for Growth/Differentiation Factor 8 (MSTN).44 fold changeStandard Deviation 0.29
p-value: 0.633ANOVA
Primary

RT-qPCR for Myocyte Enhancer Factor 2A (MEF2a)

RT-qPCR for Myocyte Enhancer Factor 2A (MEF2a) \[mRNA response of MEF2a\] Fold change calculated using the delta, delta CT method relative to stable reference genes and pre-exercise measures.

Time frame: 4-hours post Exercise

ArmMeasureValue (MEAN)Dispersion
Muscle CoolingRT-qPCR for Myocyte Enhancer Factor 2A (MEF2a)1.44 fold changeStandard Deviation 1.28
ControlRT-qPCR for Myocyte Enhancer Factor 2A (MEF2a)1.91 fold changeStandard Deviation 2.12
p-value: 0.385ANOVA
Primary

RT-qPCR for Myogenic Differentiation 1 (MYOD1)

RT-qPCR for Myogenic Differentiation 1 (MYOD1) \[mRNA response of MYOD1\] Fold change calculated using the delta, delta CT method relative to stable reference genes and pre-exercise measures.

Time frame: 4-hours post Exercise

ArmMeasureValue (MEAN)Dispersion
Muscle CoolingRT-qPCR for Myogenic Differentiation 1 (MYOD1)2.08 fold changeStandard Deviation 1.73
ControlRT-qPCR for Myogenic Differentiation 1 (MYOD1)1.92 fold changeStandard Deviation 1.6
p-value: 0.665ANOVA
Primary

RT-qPCR for Myogenic Factor 5 (MYF5)

RT-qPCR for Myogenic Factor 5 (MYF5) \[mRNA response of MYF5\] Fold change calculated using the delta, delta CT method relative to stable reference genes and pre-exercise measures.

Time frame: 4-hours post Exercise

ArmMeasureValue (MEAN)Dispersion
Muscle CoolingRT-qPCR for Myogenic Factor 5 (MYF5).51 fold changeStandard Deviation 0.21
ControlRT-qPCR for Myogenic Factor 5 (MYF5).83 fold changeStandard Deviation 0.55
p-value: 0.076ANOVA
Primary

RT-qPCR for Myogenic Factor 6 (MYF6)

RT-qPCR for Myogenic Factor 6 (MYF6) \[mRNA response of MYF6\] Fold change calculated using the delta, delta CT method relative to stable reference genes and pre-exercise measures.

Time frame: 4-hours post Exercise

ArmMeasureValue (MEAN)Dispersion
Muscle CoolingRT-qPCR for Myogenic Factor 6 (MYF6)2.2 fold changeStandard Deviation 1.7
ControlRT-qPCR for Myogenic Factor 6 (MYF6)1.32 fold changeStandard Deviation 0.47
p-value: 0.151ANOVA
Primary

RT-qPCR for Myogenin (MYOG)

RT-qPCR for Myogenin (MYOG) \[mRNA response of MYOG\] Fold change calculated using the delta, delta CT method relative to stable reference genes and pre-exercise measures.

Time frame: 4-hours post Exercise

ArmMeasureValue (MEAN)Dispersion
Muscle CoolingRT-qPCR for Myogenin (MYOG)1.88 fold changeStandard Deviation 1.75
ControlRT-qPCR for Myogenin (MYOG)2.62 fold changeStandard Deviation 1.33
p-value: 0.078ANOVA
Primary

RT-qPCR for Ribosomal Protein L3 Like (RPL3L)

RT-qPCR for Ribosomal Protein L3 Like (RPL3L) \[mRNA response of RPL3L\] Fold change calculated using the delta, delta CT method relative to stable reference genes and pre-exercise measures.

Time frame: 4-hours post Exercise

ArmMeasureValue (MEAN)Dispersion
Muscle CoolingRT-qPCR for Ribosomal Protein L3 Like (RPL3L)1.55 fold changeStandard Deviation 1.57
ControlRT-qPCR for Ribosomal Protein L3 Like (RPL3L).78 fold changeStandard Deviation 0.34
p-value: 0.118ANOVA
Primary

RT-qPCR for Ribosomal Protein S3 (RPS3)

RT-qPCR for Ribosomal Protein S3 (RPS3) \[mRNA response of RPS3\] Fold change calculated using the delta, delta CT method relative to stable reference genes and pre-exercise measures.

Time frame: 4-hours post Exercise

ArmMeasureValue (MEAN)Dispersion
Muscle CoolingRT-qPCR for Ribosomal Protein S3 (RPS3)1.46 fold changeStandard Deviation 1.55
ControlRT-qPCR for Ribosomal Protein S3 (RPS3)1.29 fold changeStandard Deviation 0.69
p-value: 0.773ANOVA
Primary

RT-qPCR for Tripartite Motif Containing 63 (TRIM63)

RT-qPCR for Tripartite Motif Containing 63 (TRIM63) \[mRNA response of TRIM63\] Fold change calculated using the delta, delta CT method relative to stable reference genes and pre-exercise measures.

Time frame: 4-hours post Exercise

ArmMeasureValue (MEAN)Dispersion
Muscle CoolingRT-qPCR for Tripartite Motif Containing 63 (TRIM63)3.59 fold changeStandard Deviation 3.4
ControlRT-qPCR for Tripartite Motif Containing 63 (TRIM63)3.50 fold changeStandard Deviation 4.43
p-value: 0.858ANOVA
Secondary

Muscle Temperature

Intramuscular Temperature

Time frame: 4-hours post Exercise

ArmMeasureValue (MEAN)Dispersion
Muscle CoolingMuscle Temperature26.09 degrees CStandard Deviation 3
ControlMuscle Temperature35.07 degrees CStandard Deviation 1.04
p-value: <0.001ANOVA
Secondary

Skin Temperature

Surface Temperature of the skin

Time frame: 4-hours post Exercise

ArmMeasureValue (MEAN)Dispersion
Muscle CoolingSkin Temperature20.4 degrees CStandard Deviation 2.01
ControlSkin Temperature31.65 degrees CStandard Deviation 2.04
p-value: <0.001ANOVA

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026